PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15803849

[COPD in the year 2005].

M John·C Witt
View original source ↗Export metadata ↓

Abstract

COPD is a widespread illness with an increasing prevalence and mortality rate. Current knowledge of its pathophysiology has it that COPD is not simply limited to the lungs, but must be understood as a systemic inflammatory reaction. The ATS/ERS guideline goes beyond the recommendations of the GOLD guideline, and takes account of the peculiarities of the European and North American healthcare systems (www.ersnet.org). In this context, the role of inhaled steroids, which is currently still under lively discussion, has to be revisited. Additional possible approaches include the administration of appetite stimulants and dietary measures, and the application of iron or erythropoietin. The TORCH study--currently the largest ongoing COPD study--is investigating the influence of inhaled glucocorticoids and long-acting beta2 agonists on mortality.

Explore related subjects

Administration, InhalationAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AgonistsBronchodilator AgentsCombined Modality TherapyExerciseGlucocorticoidsHumansLong-Term CareMulticenter Studies as TopicPatient Education as TopicPractice Guidelines as TopicPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M John, C Witt. 2005-03-17. [COPD in the year 2005].. https://pubmed.ncbi.nlm.nih.gov/15803849/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗